Advertisement

Advertisement
Myelodysplastic Syndromes

PANTHER: No Significant Benefit for Pevonedistat Plus Azacitidine in Higher-Risk Myelodysplastic Syndrome

The phase III PANTHER trial, which evaluated pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and low–blast count acute myeloid leukemia (AML), failed to meet its primary endpoint of event-free survival, though lessons were learned that are applicable in the clinic, said lead investigator Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

 

 

 

 

 

Gastroesophageal Cancer

Pretreatment Cardiovascular Disease and Events During Follow-up in Patients Receiving Curative-Intent Chemoradiation for Esophageal Cancer

In a Danish single-institution study reported in JACC: CardioOncology, Søndergaard et al found a high rate of undetected or inadequately treated preexisting cardiovascular disease prior to the receipt of chemoradiation and a high rate of cardiovascular events during follow-up in patients undergoing curative treatment for esophageal cancer.

 

 

 

 

 

 

 

 

 

 

Gynecologic Cancers
Immunotherapy

Pembrolizumab in Previously Treated Patients With MSI-H/dMMR Endometrial Cancer

As reported in the Journal of Clinical Oncology by David M. O’Malley, MD, and colleagues, pembrolizumab showed durable activity in a cohort of patients with microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) advanced endometrial cancer enrolled in the multicohort KEYNOTE-158 study.

 


Advertisement
Breast Cancer

Does Early Locoregional Therapy for the Primary Site Improve Survival in Newly Diagnosed Metastatic Breast Cancer?

In the phase III ECOG-ACRIN E2108 trial reported in the Journal of Clinical Oncology, Seema A. Khan, MD, MPH, and colleagues found no difference in overall survival with early locoregional therapy vs continued systemic therapy among women with newly diagnosed stage IV breast cancer and an intact primary tumor site.

 

 

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Breast Cancer

Melinda L. Telli, MD, on Breast Cancer: Neoadjuvant Talazoparib for Early HER2-Negative Disease

Leukemia
Immunotherapy

Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL

The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Issues in Oncology

Ralph R. Weichselbaum, MD, on Oligometastasis: Biologic Basis and Therapeutic Opportunities

Breast Cancer
Immunotherapy

Adjuvant Trastuzumab Emtansine vs Paclitaxel/Trastuzumab in Stage I HER2-Positive Breast Cancer

In the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that adjuvant trastuzumab emtansine (T-DM1) resulted in “excellent” invasive disease–free survival but did not reduce clinically relevant toxicity compared with...

Breast Cancer
Immunotherapy

Adjuvant Trastuzumab Emtansine vs Paclitaxel/Trastuzumab in Stage I HER2-Positive Breast Cancer

In the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that adjuvant trastuzumab emtansine (T-DM1) resulted in “excellent” invasive disease–free survival but did not reduce clinically relevant toxicity compared with...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Issues in Oncology

Narjust Duma, MD, and Gladys I. Rodriguez, MD, on A First for Hispanic Women: Formation of a YIA for Latinas

Skin Cancer
Immunotherapy

Extended Follow-up of Nivolumab/Ipilimumab for Metastatic Melanoma

In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive at a median of 6.5 years after treatment. These long-term results from the...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...